Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

Company Overview

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Key Stats

• Today's Range: $13.59 to $14.35
• 50-Day Range: $11.97 to $20.25
• 52-Week Range: $3.18 to $21.48
• Volume: 417,631 shs
• Average Volume: 225,839 shs
• Market Capitalization: $365.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.67
• Consensus Rating: Buy

Eton Pharmaceuticals Stock Analysis - MarketRank™

Eton Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 575th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Eton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eton Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eton Pharmaceuticals is -75.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eton Pharmaceuticals is -75.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eton Pharmaceuticals has a P/B Ratio of 14.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.51% of the float of Eton Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eton Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eton Pharmaceuticals has recently increased by 39.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eton Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eton Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.51% of the float of Eton Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eton Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eton Pharmaceuticals has recently increased by 39.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.37

News Sentiment

Eton Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Eton Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $504,318.00 in company stock.

Percentage Held by Insiders

14.89% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.86% of the stock of Eton Pharmaceuticals is held by institutions.

ETON Stock Analysis - Frequently Asked Questions

How have ETON shares performed this year?

Eton Pharmaceuticals' stock was trading at $13.32 at the start of the year. Since then, ETON shares have increased by 2.2% and is now trading at $13.61.
View the best growth stocks for 2025 here.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings results on Tuesday, May, 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by $0.02. The business earned $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 3.15% and a negative net margin of 9.49%.
Read the conference call transcript.

When did Eton Pharmaceuticals IPO?

Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' top institutional investors include Nantahala Capital Management LLC (4.38%), Westside Investment Management Inc. (1.84%), Acadian Asset Management LLC (1.50%) and Millennium Management LLC (1.33%). Insiders that own company stock include Opaleye Management Inc, Sean Brynjelsen and David Krempa.
View institutional ownership trends.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ETON
• CIK: 1710340
• Web: www.etonpharma.com
• Phone: (847) 787-7361
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.67
• High Stock Price Target: $35.00
• Low Stock Price Target: $26.00
• Potential Upside/Downside: +118.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.82 million
• Net Margins: -9.49%
• Pretax Margin: -9.30%
• Return on Equity: -3.15%
• Return on Assets: -1.08%

Debt

• Debt-to-Equity Ratio: 1.23
• Current Ratio: 1.97
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: $39.01 million
• Price / Sales: 9.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 14.48

Miscellaneous

• Outstanding Shares: 26,820,000
• Free Float: 22,825,000
• Market Cap: $365.02 million
• Optionable: Optionable
• Beta: 1.28